8-K: CG Oncology Announces First Quarter 2025 Financial Results and Provides Clinical Program Updates

CG Oncology reported its Q1 2025 financial results and highlighted promising clinical trial updates, including positive data from its BOND-003 and CORE-008 trials for bladder cancer treatment.

Summary

• CG Oncology reported financial results for the first quarter ended March 31, 2025.
• The company is advancing cretostimogene monotherapy as a bladder-sparing therapy for NMIBC patients.
• BOND-003 Cohort C data presented at AUA showed best-in-disease durability and tolerability.
• The company plans to initiate a BLA submission in the second half of the year for HR NMIBC unresponsive to BCG.
• Early data from Cohort P showed 90.5% high-grade recurrence-free survival at 3 and 9 months.
• CORE-008 Cohort CX was initiated to evaluate cretostimogene and gemcitabine in HR BCG-exposed NMIBC patients.
• Cash and cash equivalents and marketable securities were $688.4 million as of March 31, 2025.
• The company expects its cash to fund operations into the first half of 2028.
• R&D expenses for Q1 2025 were $27.5 million, compared to $17.2 million in Q1 2024.
• G&A expenses for Q1 2025 were $14.8 million, compared to $5.8 million in Q1 2024.
• Net loss was $34.5 million, or ($0.45) per share, for Q1 2025, compared to $16.9 million, or ($0.36) per share, for Q1 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to promising clinical trial results and a strong cash position, but tempered by increased net losses and expenses.

Positives

• BOND-003 Cohort C data shows best-in-disease durability and tolerability.
• Cohort P shows promising early signal with high recurrence-free survival rates.
• The company has a strong cash position of $688.4 million, expected to fund operations into the first half of 2028.
• The company is initiating a BLA submission for cretostimogene monotherapy in HR BCG-unresponsive NMIBC in the second half of 2025.

Negatives

• Net loss increased to $34.5 million, or ($0.45) per share, for Q1 2025, compared to $16.9 million, or ($0.36) per share, for Q1 2024.
• R&D and G&A expenses increased significantly compared to the same quarter last year.

Risks

• Interim results of clinical trials are not necessarily indicative of final results.
• There may be potential delays in the commencement, enrollment, and completion of clinical trials.
• The company may use its capital resources sooner than expected.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene may limit its development, regulatory approval, and/or commercialization.

Future Outlook

The company anticipates initiating a BLA submission for cretostimogene monotherapy in HR BCG-unresponsive NMIBC in the second half of 2025 and expects to complete Phase 3 enrollment for PIVOT-006 in intermediate-risk NMIBC in the same period. The company expects its cash to fund operations into the first half of 2028.

Management Comments

• In 2025, we made further progress advancing cretostimogene monotherapy as a bladder-sparing backbone therapy for patients with NMIBC, said Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology.
• With best-in-disease durability and tolerability data from the BOND-003 Cohort C registrational trial recently presented at AUA, we are well positioned to initiate our BLA submission in the second half of the year for the treatment of patients with HR NMIBC unresponsive to BCG.
• If approved, Im confident that cretostimogene is well positioned to become backbone therapy in NMIBC, potentially addressing more than 70% of the market opportunity in need of a new and innovative therapy.

Industry Context

CG Oncology is focused on developing bladder-sparing therapies for bladder cancer, a significant unmet need in the urologic oncology space. The company's cretostimogene aims to address a large portion of the NMIBC market, competing with existing treatments like BCG and offering a potential alternative for patients unresponsive to BCG.

Comparison to Industry Standards

• The 24-month complete response rate of 42.3% in BOND-003 Cohort C is competitive compared to existing therapies for BCG-unresponsive NMIBC.
• Companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo) have approved immunotherapies for bladder cancer, but CG Oncology's cretostimogene offers a potential bladder-sparing approach.
• The 90.5% high-grade recurrence-free survival at 3 and 9 months in Cohort P is a promising early signal compared to recurrence rates observed with standard treatments for Ta/T1 papillary disease.

Stakeholder Impact

• Shareholders may react positively to the clinical trial updates and strong cash position.
• Patients with bladder cancer may benefit from the development of cretostimogene as a potential bladder-sparing therapy.
• Employees may experience increased job security due to the company's financial stability.

Next Steps

• Initiation of BLA submission for cretostimogene monotherapy in HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease in the second half of 2025.
• Completion of Phase 3 enrollment for PIVOT-006 in intermediate-risk NMIBC in the second half of 2025.
• Topline data from the Phase 3 clinical trial of cretostimogene monotherapy for BOND-003 Cohort P (HR BCG-unresponsive NMIBC in Ta/T1 disease without CIS) in the second half of 2025.
• Topline data from the Phase 2 clinical trial of cretostimogene monotherapy for CORE-008 Cohort A (HR BCG-nave NMIBC with CIS +/Ta/T1).

Key Dates

Keywords

CG Oncology, cretostimogene, NMIBC, bladder cancer, clinical trial, BOND-003, PIVOT-006, CORE-008, financial results, BLA submission